ANP 014
Alternative Names: ANP-014Latest Information Update: 30 Oct 2020
At a glance
- Originator ANP Technologies
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 28 Oct 2020 ANP 014 is available for licensing as of 28 Oct 2020. https://www.anptinc.com/
- 28 Oct 2020 Preclinical trials in Triple negative Breast cancer in USA (ANP Technologies pipeline, October 2020)
- 28 Oct 2020 ANP Technologies plans to submit an IND application for ANP 014 for Breast cancer (ANP Technologies website, October 2020)